Cardiovascular Systems Inc (CSII):製品パイプライン分析

◆英語タイトル:Cardiovascular Systems Inc (CSII) - Product Pipeline Analysis, 2017 Update
◆商品コード:DATA8010070
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月27日
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD750 ⇒換算¥109,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD1,500 ⇒換算¥219,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD2,250 ⇒換算¥328,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cardiovascular Systems Inc (CSI) is a medical device company that develops and commercializes products for treating peripheral and coronary vascular disease. The company offers products such as peripheral orbital atherectomy system, coronary orbital atherectomy system, crowns, and accessories. Its PAD system is a percutaneous orbital atherectomy system that is used as therapy for occlusive atherosclerotic disease in peripheralarteries and stenotic material from artificial arteriovenous dialysis fistulae. CSI offers accessories such as guide wire, lubricant, pump and tape. The company serves patients suffering from peripheral arterial disease and coronary artery diseases. It markets its products through its network of distributors. CSI is headquartered in St. Paul, Minnesota, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Cardiovascular Systems Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Cardiovascular Systems Inc Company Overview 4
Cardiovascular Systems Inc Company Snapshot 4
Cardiovascular Systems Inc Pipeline Products and Ongoing Clinical Trials Overview 4
Cardiovascular Systems Inc – Pipeline Analysis Overview 7
Cardiovascular Systems Inc – Key Facts 7
Cardiovascular Systems Inc – Major Products and Services 8
Cardiovascular Systems Inc Pipeline Products by Development Stage 9
Cardiovascular Systems Inc Ongoing Clinical Trials by Trial Status 11
Cardiovascular Systems Inc Pipeline Products Overview 13
Diamondback 360 Coronary OAS Micro Crown 13
Diamondback 360 Coronary OAS Micro Crown Product Overview 13
Diamondback 360 Coronary Orbital Atherectomy System 14
Diamondback 360 Coronary Orbital Atherectomy System Product Overview 14
Diamondback 360 Coronary Orbital Atherectomy System Clinical Trial 15
Diamondback 360 Peripheral Orbital Atherectomy System 16
Diamondback 360 Peripheral Orbital Atherectomy System Product Overview 16
Diamondback 360 Peripheral Orbital Atherectomy System Clinical Trial 17
Cardiovascular Systems Inc – Key Competitors 18
Cardiovascular Systems Inc – Key Employees 19
Cardiovascular Systems Inc – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Cardiovascular Systems Inc, Recent Developments 21
Oct 25, 2017: Cardiovascular Systems Reports Fiscal 2018 First-Quarter Financial Results 21
Sep 18, 2017: Cardiovascular Systems Announces Anticipated Revenue Impact from Hurricanes Harvey and Irma 22
Sep 11, 2017: Lesion Preparation Using Diamondback 360 Orbital Atherectomy System Enhances Paclitaxel Distribution in Calcified Peripheral Arteries 22
Aug 10, 2017: LIBERTY 360° Study 12-Month Data Demonstrate Lasting Benefits Following Endovascular Intervention in Patients with Critical Limb Ischemia 23
Aug 10, 2017: LIBERTY 360° Study 12-Month Sub-Analysis Reveals High Freedom from Major Amputation and Major Adverse Events (MAE) Using Cardiovascular Systems’ Diamondback 360 Peripheral Orbital Atherectomy System (OAS) 24
Aug 02, 2017: Cardiovascular Systems Reports Fiscal 2017 Fourth-Quarter Financial Results 24
May 04, 2017: FDA Approves Cardiovascular Systems’ Replacement Saline Infusion Pump 26
May 03, 2017: Cardiovascular Systems Reports Fiscal 2017 Third-Quarter Financial Results 26
Apr 17, 2017: Cardiovascular Systems Initiates Voluntary Recall of Saline Infusion Pump 27
Mar 30, 2017: Cardiovascular Systems Receives Approval for the Diamondback 360 Coronary Orbital Atherectomy System Micro Crown in the United States 28
Appendix 29
Methodology 29
About GlobalData 31
Contact Us 31
Disclaimer 32

List of Tables
Cardiovascular Systems Inc Pipeline Products and Ongoing Clinical Trials Overview 4
Cardiovascular Systems Inc Pipeline Products by Equipment Type 5
Cardiovascular Systems Inc Pipeline Products by Indication 6
Cardiovascular Systems Inc Ongoing Clinical Trials by Trial Status 6
Cardiovascular Systems Inc, Key Facts 7
Cardiovascular Systems Inc, Major Products and Services 8
Cardiovascular Systems Inc Number of Pipeline Products by Development Stage 9
Cardiovascular Systems Inc Pipeline Products Summary by Development Stage 10
Cardiovascular Systems Inc Ongoing Clinical Trials by Trial Status 11
Cardiovascular Systems Inc Ongoing Clinical Trials Summary 12
Diamondback 360 Coronary OAS Micro Crown - Product Status 13
Diamondback 360 Coronary OAS Micro Crown - Product Description 13
Diamondback 360 Coronary Orbital Atherectomy System - Product Status 14
Diamondback 360 Coronary Orbital Atherectomy System - Product Description 14
Diamondback 360 Coronary Orbital Atherectomy System - Comparison of Orbital Versus Rotational Atherectomy Effects on Coronary Microcirculation in Percutaneous Coronary Intervention (PCI) 15
Diamondback 360 Coronary Orbital Atherectomy System - Evaluation of Treatment Strategies for Severe CalcIfic Coronary Arteries: Orbital Atherectomy versus Conventional Angioplasty Technique Prior to Implantation of Drug-eluting Stents: The ECLIPSE Trial 15
Diamondback 360 Peripheral Orbital Atherectomy System - Product Status 16
Diamondback 360 Peripheral Orbital Atherectomy System - Product Description 16
Diamondback 360 Peripheral Orbital Atherectomy System - Orbital Vessel Preparation to Maximize DCB Efficacy in Calcified below the Knee (BTK) Lesions - A Pilot Study 17
Diamondback 360 Peripheral Orbital Atherectomy System - Prospective, Observational, Multi-center Clinical Study to Evaluate Acute and Long Term Clinical and Economic Outcomes of Endovascular Device Intervention in Patients with Distal Outflow Peripheral Arterial Disease (PAD): LIBERTY 360 17
Cardiovascular Systems Inc, Key Employees 19
Glossary 30

★海外企業調査レポート[Cardiovascular Systems Inc (CSII):製品パイプライン分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NMDC Ltd:企業の戦略・SWOT・財務情報
    NMDC Ltd - Strategy, SWOT and Corporate Finance Report Summary NMDC Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Coloplast A/S:企業の戦略・SWOT・財務情報
    Coloplast A/S - Strategy, SWOT and Corporate Finance Report Summary Coloplast A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Albemarle Corporation:企業の戦略・SWOT・財務情報
    Albemarle Corporation - Strategy, SWOT and Corporate Finance Report Summary Albemarle Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Zurich UK:企業の戦略・SWOT・財務情報
    Zurich UK - Strategy, SWOT and Corporate Finance Report Summary Zurich UK - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Heat Biologics Inc (HTBX):企業の財務・戦略的SWOT分析
    Heat Biologics Inc (HTBX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Standard Chem & Pharm Co Ltd:企業の戦略・SWOT・財務分析
    Standard Chem & Pharm Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Standard Chem & Pharm Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Terrain Energy Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Terrain Energy Ltd (Terrain Energy) is an oil and gas company that offers oil and gas exploration and production services. The company’s services include acquiring, operations, production, management and development of oil and gas producing basins in the onshore UK. It owns and operates onsh …
  • Prasco LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Prasco LLC (Prasco Laboratories) is a pharmaceutical company that manufactures and markets authorized generic and generic products. The company’s authorized generic products include acitretin capsules, clotrimazole and betamethasone dipropionate cream, atovaquone and proguanil HCl tablets, c …
  • HomeStay Care Ltd (HSC):企業の財務・戦略的SWOT分析
    HomeStay Care Ltd (HSC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Opsona Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Opsona Therapeutics Ltd (Opsona) is a biopharmaceutical company that conducts research, develops and commercializes new treatment for the autoimmune and inflammatory diseases and cancers. The company's OPN-305 is a humanized antibody used to reduce pro-inflammatory cytokine production that i …
  • Vallourec SA:企業の戦略・SWOT・財務情報
    Vallourec SA - Strategy, SWOT and Corporate Finance Report Summary Vallourec SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Culture Landmark Investment Ltd:企業の戦略・SWOT・財務分析
    Culture Landmark Investment Ltd - Strategy, SWOT and Corporate Finance Report Summary Culture Landmark Investment Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Cochlear Ltd (COH):医療機器:M&Aディール及び事業提携情報
    Summary Cochlear Ltd (Cochlear) is a medical device company that offers implantable hearing solutions. It develops, manufactures and markets electronic implantable hearing devices. The company’s products are suited for people with hearing loss caused by ear nerve damage. Its major products include c …
  • International Coffee & Tea, LLC:企業の戦略・SWOT・財務情報
    International Coffee & Tea, LLC - Strategy, SWOT and Corporate Finance Report Summary International Coffee & Tea, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Enterome Bioscience SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Enterome Bioscience SA (Enterome) is a drug development company which develops medical tests, and companion diagnostics to develop the management of microbiome-related diseases. The company develops medical tests based on its metagenotype technology platform that helps to identify microbiome …
  • PharmaCyte Biotech Inc (PMCB):企業の財務・戦略的SWOT分析
    Summary PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc, is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company offers technology is used for the treatment of advanced and inoperable pancreatic cancer and diabetes. It deve …
  • MedNet Solutions Inc-医療機器分野:企業M&A・提携分析
    Summary MedNet Solutions Inc (MedNet Solutions) is a healthcare technology company which provides eClinical and electronic data capture software solutions. The company developed iMedNet, an eClinical technology platform which provides non – technical clinical research for clinical trials or studies. …
  • Idexx Laboratories Inc (IDXX):企業の財務・戦略的SWOT分析
    Idexx Laboratories Inc (IDXX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Selex Gruppo Commerciale S.p.A.:企業の戦略・SWOT・財務情報
    Selex Gruppo Commerciale S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Selex Gruppo Commerciale S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • The Chemours Company LLC:企業の戦略・SWOT・財務情報
    The Chemours Company LLC - Strategy, SWOT and Corporate Finance Report Summary The Chemours Company LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆